It started as a whisper. Patients on semaglutide for weight loss began telling their doctors something unexpected: they didn’t want to drink anymore. Not through white-knuckle willpower—they simply lost interest. The beer that used to call their name after work? They could take it or leave it. The nightly glass of wine? It didn’t sound appealing.
Those anecdotal reports caught the attention of addiction researchers. And in 2025, the first randomized controlled trial confirmed what patients had been saying all along: semaglutide significantly reduces alcohol consumption and cravings.
The JAMA Psychiatry Trial: First Real Evidence
Published in JAMA Psychiatry in early 2025, a randomized controlled trial led by Dr. Christian Hendershot at the USC Institute for Addiction Science was the first rigorous test of semaglutide for alcohol use disorder (AUD). The trial enrolled patients with diagnosed AUD and measured both drinking behavior and cravings over the study period.
The results showed significant reductions in alcohol consumption and cravings among participants receiving semaglutide compared to placebo. This was not a weight-loss trial that happened to notice drinking changes—it was specifically designed to test whether semaglutide could help people drink less.
Why This Matters
Alcohol use disorder affects approximately 29 million Americans. Current FDA-approved treatments (naltrexone, acamprosate, disulfiram) have modest effectiveness and are underutilized. If GLP-1 medications prove effective for AUD, they could represent a major new treatment option—especially for patients who also struggle with obesity.
How GLP-1s Affect the Brain’s Reward System
The connection between GLP-1 medications and reduced addictive behavior isn’t random. GLP-1 receptors are expressed throughout the brain’s reward circuitry—the same neural pathways that drive cravings for alcohol, nicotine, and other substances.
Here’s what researchers believe is happening:
- Dopamine modulation: GLP-1 receptors in the ventral tegmental area (VTA) and nucleus accumbens—the brain’s core reward centers—appear to dampen the dopamine surge triggered by addictive substances. The “reward signal” from alcohol or nicotine becomes weaker.
- Reduced craving intensity: Just as GLP-1s reduce “food noise” (the constant mental chatter about eating), they appear to reduce “substance noise”—the intrusive thoughts and cravings that drive addictive behavior.
- Habenular circuits: Research published in Nature Neuroscience by Tuesta et al. identified GLP-1 receptor activity in the habenula, a brain region involved in avoidance behavior. Activating these receptors may help the brain “learn” to avoid substances more effectively.
- Liver protection: Yale research found that GLP-1s decrease the liver enzyme that converts alcohol into toxic acetaldehyde, providing direct hepatoprotection independent of drinking reduction.
Nicotine and Smoking: Active Clinical Trials
The nicotine angle is equally promising. The University of North Carolina launched a clinical trial specifically studying the effects of semaglutide on nicotine intake. Eli Lilly has also announced trials investigating GLP-1 medications for smoking cessation.
The mechanism is similar to alcohol: GLP-1 receptors in the brain’s reward pathways modulate the dopamine response to nicotine. Preclinical studies have shown that GLP-1 receptor activation reduces nicotine self-administration in animal models, and FAERS (FDA Adverse Event Reporting System) data has flagged smoking cessation as an unexpected “side effect” reported by patients taking GLP-1 medications.
With approximately 30 million American adults currently smoking cigarettes and smoking remaining the leading cause of preventable death, a medication that helps with both weight management and smoking cessation simultaneously would be transformative.
Beyond Alcohol and Nicotine: Other Addictive Behaviors
The addiction research doesn’t stop at alcohol and nicotine. Researchers are investigating GLP-1’s impact on several other compulsive behaviors:
- Opioid use disorder: A Stanford analysis found that GLP-1 users had approximately 40% lower rates of opioid overdose compared to matched controls. Phase 2 trials are underway.
- Cannabis use disorder: A 2024 study published in Molecular Psychiatry by Wang et al. showed a 44% reduction in cannabis use disorder diagnoses among GLP-1 users.
- Gambling and compulsive behaviors: While no clinical trials exist yet, anecdotal reports from patients describe reduced compulsive gambling, shopping, and other reward-driven behaviors. Dr. Nora Volkow, director of the National Institute on Drug Abuse (NIDA), has commented publicly that GLP-1’s effects on behavioral addictions warrant serious investigation.
What We Don’t Know Yet
It’s important to keep the evidence in perspective. While the early data is exciting, several important questions remain:
- Optimal dosing: The dose that works best for addiction may differ from the dose optimized for weight loss. Trials are still determining the right approach.
- Duration of effect: Does the anti-craving benefit persist long-term, or does it fade? The longest studies are still relatively short.
- Who benefits most: Not all patients report reduced cravings. Identifying who is most likely to respond is an active area of research.
- Mechanism clarity: While the dopamine modulation theory is well-supported, the exact pathway by which GLP-1s reduce cravings is still being mapped.
- FDA approval for addiction: GLP-1 medications are not currently FDA-approved for any addiction indication. Phase 3 trials for alcohol use disorder are underway, but approval is likely years away.
What This Means for You
If you’re taking a GLP-1 medication for weight management and notice that your interest in alcohol or nicotine has decreased, you’re not imagining things. This is a real, biologically plausible effect that thousands of patients have reported and that clinical research now supports.
However, GLP-1 medications should not be used as a stand-alone treatment for alcohol or nicotine addiction. If you struggle with substance use, work with a healthcare provider who specializes in addiction medicine. GLP-1s may become part of the treatment toolkit in the future, but they are not yet approved for this purpose.
The fact that a single medication class can simultaneously address obesity, cardiovascular risk, kidney disease, and potentially addictive behaviors speaks to how deeply GLP-1 receptors are wired into the body’s fundamental regulatory systems. The full scope of what these medications can do is still being discovered.
Sources
- Hendershot CS, et al. JAMA Psychiatry. 2025;82(4):395-405. DOI: 10.1001/jamapsychiatry.2024.4789
- Tuesta LM, et al. “GLP-1 acts on habenular avoidance circuits.” Nature Neuroscience. 2017.
- Wang L, et al. “GLP-1 receptor agonists and cannabis use disorder.” Molecular Psychiatry. 2024.
- ClinicalTrials.gov. “Effects of Semaglutide on Nicotine Intake.” University of North Carolina.
- Volkow ND. NIDA commentary on GLP-1 receptor agonists and addiction. 2024-2025.